Using Mach's number for the potential cost of each N-Assay kit ($200.00) and "result in sales of multiple thousands of N-Assay kits" from the multi-billion medical technology company, that's a MIN of $400k in revenue. I don't think they'll be able to keep the share pice down anywhere near $0.03 for much longer.